Who are Contineum Therapeutics, Inc.'s main suppliers?

Contineum Therapeutics, Inc. (CTNM) key suppliers include: GOLDMAN-SACHS-CO-LLC, LEERINK-PARTNERS-LLC. View the full supplier network at chainsifter.com/chain/CTNM.

Who are Contineum Therapeutics, Inc.'s major customers?

Contineum Therapeutics, Inc. (CTNM) key customers include: J-J, JJDC. View the full customer network at chainsifter.com/chain/CTNM.

What sector is Contineum Therapeutics, Inc. in?

Contineum Therapeutics, Inc. (CTNM) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

CTNM Supply Chain: Contineum Therapeutics, Inc. Suppliers & Customers

2Suppliers

2Customers

3Debt Items

20Related Chains

Contineum Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
GOLDMAN-SACHS-CO-LLC	GOLDMAN-SACHS-CO-LLC	90%	The Underwriters purchased the Shares from the Company pursuant to the Underwriting Agreement
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	90%	On May 14, 2025, the Company entered into a Sales Agreement with Leerink Partners LLC, pursuant to which the Company may from time to time issue and sell through Leerink Partners, acting as the Compa…

Contineum Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
J-J	J-J	92%	Pursuant to the terms of the J&J License Agreement, the Company granted J&J an exclusive, worldwide license to develop, manufacture and commercialize PIPE-307 in all indications.
JJDC	JJDC	90%	Separately, we received a $25.0 million equity investment from JJDC.

Contineum Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CTNM-DEBT-8911	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.
CTNM-DEBT-8910	Warrants outstanding: 0	90%	xbrl warrant detail from xbrl 2025-12-31.
CTNM-DEBT	Debt stack $7.0M	90%	Market cache reports total debt of $7.0M.

Contineum Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Contineum Therapeutics, Inc..

Contineum Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
CTNM-OWNER-JOHNSON-JOHNSON	JOHNSON & JOHNSON	90%	13F overlay lists JOHNSON & JOHNSON as top holder; 91 tracked holders.

Contineum Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ALLO	Allogene Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
NVO	Novo Nordisk A/S	100.00	2
SLGL	Sol-Gel Technologies Ltd.	100.00	2
BDRX	Biodexa Pharmaceuticals Plc	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
DEO	Diageo plc	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2

Contineum Therapeutics, Inc. Supply Chain